EDP-938 Dose 1 + EDP-938 Dose 2 + Placebo + EDP-938 Dose 3 + EDP-938 Dose 4 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

RSV Infection

Conditions

RSV Infection

Trial Timeline

Oct 15, 2018 → Oct 18, 2019

NCT ID

NCT03691623

About EDP-938 Dose 1 + EDP-938 Dose 2 + Placebo + EDP-938 Dose 3 + EDP-938 Dose 4 + Placebo

EDP-938 Dose 1 + EDP-938 Dose 2 + Placebo + EDP-938 Dose 3 + EDP-938 Dose 4 + Placebo is a phase 2 stage product being developed by Enanta Pharmaceuticals for RSV Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03691623. Target conditions include RSV Infection.

What happened to similar drugs?

20 of 20 similar drugs in RSV Infection were approved

Approved (20) Terminated (3) Active (0)

✅Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved

✅Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved

✅amphotericin B liposomal (Ambisome)Astellas PharmaApproved

✅Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved

✅Cefiderocol + Ampicillin-sulbactam + Colistin + MeropenemJohnson & JohnsonApproved

✅Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved

✅Lopinavir/RitonavirAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03691623	Phase 2	Completed	Oct 15, 2018	Oct 18, 2019	RSV Infection

Competing Products

20 competing products in RSV Infection

See all competitors

Product	Company	Stage	Hype Score
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1944	Moderna	Phase 1	0
mRNA-1189	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1653	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1653	Moderna	Phase 1	0
mRNA-1195.1	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 3	0
DFA-02 Antibiotic Gel + DFA-02 Placebo Gel	Dr. Reddy's Laboratories	Phase 2	32
DFA-02 + Placebo	Dr. Reddy's Laboratories	Phase 1/2	29
Levofloxacin + Levofloxacin	Dr. Reddy's Laboratories	Approved	36
BSG005	Alkem Laboratories	Phase 1/2	39
Zotatifin + Placebo	eFFECTOR Therapeutics	Phase 1	19
AAVLP-HPV + Placebo	2A Pharma	Phase 1	19
CT-P59	Celltrion	Phase 1	29
CT-P63 + Placebo	Celltrion	Phase 1	29